News bites
Vaccines for GAVI
Pfizer and GlaxoSmithKline have entered into separate agreements with the GAVI Alliance to supply pneumococcal vaccines to
developing countries. Each company has agreed to supply as many as 480 million doses of their pneumococcal vaccines
Read more at
http://www.PharmTech.com/gavivaccines
BMS acquires Inhibitex
In a deal worth almost €2 billion, Bristol-Myers Squibb has commenced a cash tender offer to purchase all outstanding shares
of Inhibitex. The transaction will provide BMS with an oral nucleotide polymerase inhibitor that is currently in Phase II
development for the treatment of hepatitis C.
Read more at
http://www.PharmTech.com/bmsdeal
Sanofi boosts start-up
Sanofi is extending a helping hand to start-up biotech company Warp Drive Bio by providing funding, access to its strains
library and expertise in natural products. Two US venture capitalist firms will also invest in the start up, with all three
offering funding that could amount during $125 million in the next five years.
Read more at
http://www.PharmTech.com/sanofiboost
Ranbaxy's consent decree
Pledging to strengthen procedures and policies to ensure data integrity and comply with cGMP, Ranbaxy has signed a consent
decree with the FDA. The company will also make a provision of $500 million to resolve liability in connection with an investigation
by the US Department of Justice.
Read more at
http://www.PharmTech.com/ranbaxy
